Monday, March 17, 2025
HomeIndustriesHealthcare

Healthcare

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial

ImmunityBio, Inc, a clinical-stage immunotherapy company, announced interim results (N=63) in its metastatic pancreatic cancer trial (QUILT 88) showing that the overall survival rate...

Center for Breakthrough Medicines and the UPenn Partner in Gene Therapy Manufacturing

The Center for Breakthrough Medicines (CBM) and the University of Pennsylvania's Gene Therapy Program (GTP) have signed a landmark collaboration agreement, to combine Penn's...

First Subject Enrolled in Phase II/III Study of Eisai’s Alzheimer Antibody

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School...

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals Inc., (“CANbridge,” stock code 1228.HK) a leading China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease...

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical

Neurimmune AG announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating...
0FansLike
0FollowersFollow
spot_img

Hot Topics